The Epigenetic Hallmarks of Cancer
Institució Catalana de Recerca i Estudis Avançats · Josep Carreras Leukaemia Research Institute · +13 more institutions
Abstract
Cancer is a complex disease in which several molecular and cellular pathways converge to foster the tumoral phenotype. Notably, in the latest iteration of the cancer hallmarks, "nonmutational epigenetic reprogramming" was newly added. However, epigenetics, much like genetics, is a broad scientific area that deserves further attention due to its multiple roles in cancer initiation, progression, and adaptive nature. Herein, we present a detailed examination of the epigenetic hallmarks affected in human cancer, elucidating the pathways and genes involved, and dissecting the disrupted landscapes for DNA methylation, histone modifications, and chromatin architecture that define the disease. Significance: Cancer is…
Citation impact
- FWCI
- 25.80
- Percentile
- 100%
- References
- 324
Authors
6- MEManel EstellerCorresponding
Institució Catalana de Recerca i Estudis Avançats, Josep Carreras Leukaemia Research Institute, Centro de Investigación Biomédica en Red de Cáncer, Universitat de Barcelona
- MAMark A. Dawson
The University of Melbourne, Peter MacCallum Cancer Centre
- CKCigall Kadoch
Broad Institute, Howard Hughes Medical Institute, Harvard University, Dana-Farber Cancer Institute
- FVFeyruz V. Rassool
University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
- PAPeter A. Jones
Van Andel Institute
Topics & keywords
- Epigenetics
- Reprogramming
- Biology
- Chromatin
- Cancer
- Histone
- DNA methylation
- Disease
Funding
- DMDr. Miriam and Sheldon G. Adelson Medical Research FoundationAward: 04-7023433
- FCFundación CellexAward: CEL007
- “C“la Caixa” FoundationAward: LCF/PR/GN18/51140001
- NINational Institutes of HealthAward: R01ES011858
- SUStand Up To CancerAward: P30 CA134274
- NHNational Health and Medical Research CouncilAward: #1196749
- AEAgencia Estatal de InvestigaciónAward: PID2021-125282OB-I00
- NCNational Cancer InstituteAwards: 2R35CA209859, P50CA254897, R01CA229240
- NINational Institute of Environmental Health SciencesAward: R01 ES011858
- DGDirecció General de Recerca, Generalitat de CatalunyaAward: 2021 SGR 01494